Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
11.62
+0.72 (6.61%)
Nov 13, 2026, 4:00 PM EST - Market closed
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Fennec Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $17.2. The average 1-year stock price forecast is 48.02% higher than the current stock price, while the lowest is $16 (+37.69%) and the highest is $18 (+54.91%).
Price Target: $17.2 (+48.02%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 9, 2026.
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +37.69% | Sep 9, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $15 → $20 | Buy | Reiterates | $15 → $20 | +72.12% | Aug 13, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $13 → $16 | Buy | Maintains | $13 → $16 | +37.69% | Aug 12, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Reiterates $16 → $18 | Buy | Reiterates | $16 → $18 | +54.91% | Aug 12, 2026 |
Unknown Analyst B. Riley Securities No rating | B. Riley Securities | Buy Initiates $16 → $18 | Buy | Initiates | $16 → $18 | +54.91% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
74.59M
from 44.64M
Increased by 67.08%
Revenue Next Year
105.38M
from 74.59M
Increased by 41.28%
EPS This Year
0.35
from -0.28
EPS Next Year
1.03
from 0.35
Increased by 197.12%
EPS and Forward PE are based on non-GAAP adjusted numbers.